The DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Statement of the American Society of Addiction Medicine Consensus Panel on the Use of Buprenorphine in Office-Based Treatment of Opioid Addiction
Abstract
OBJECTIVES: Opioid addiction affects over 2 million patients in the United States. The advent of buprenorphine and the passage of the Drug Addiction Treatment Act in 2000 have revolutionized the opioid treatment delivery system by granting physicians the ability to administer office-based opioid treatment (OBOT), thereby giving patients greater access to treatment. The purpose of this consensus panel was to synthesize the most current evidence on the use of buprenorphine in the office-based setting and to make recommendations that will enable and allow additional physicians to begin to treat opioid-addicted individuals. METHODS: Literature published from 2000 to 2009 was searched using the PubMed search engine and yielded over 375 articles published in peer-reviewed journals, including some that were published guidelines. These articles were submitted to a consensus panel composed of researchers, educators, and clinicians who are leaders in the field of addiction medicine with specific expertise in the use of OBOT. The panel discussed results and agreed upon consensus recommendations for several facets of OBOT. RESULTS: : On the basis of the literature review and consensus discussions, the panel developed a series of findings, conclusions, and recommendations regarding the use of buprenorphine in office-based treatment of opioid addiction. CONCLUSIONS: Therapeutic outcomes for patients who self-select office-based treatment with buprenorphine are essentially comparable to those seen in patients treated with methadone programs. There are few absolute contraindications to the use of buprenorphine, although the experience and skill levels of treating physicians can vary considerably, as can access to the resources needed to treat comorbid medical or psychiatric conditions--all of which affect outcomes. It is important to conduct a targeted assessment of every patient to confirm that the provider has resources available to meet the patient's needs. Patients should be assessed for a broad array of biopsychosocial needs in addition to opioid use and addiction, and should be treated, referred, or both for help in meeting all their care needs, including medical care, psychiatric care, and social assistance. Current literature demonstrates promising efficacy of buprenorphine, though further research will continue to demonstrate its effectiveness for special populations, such as adolescents, pregnant women, and other vulnerable populations. Since the time of this review, several new studies have provided new data to continue to improve our understanding of the safety and efficacy of buprenorphine for special patient populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
The Neural Basis of Addiction: A Pathology of Motivation and Choice
Kalivas, P. W., & Volkow, N. D. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.8.1403 · Cited by 2,757
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
Neonatal Abstinence Syndrome after Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O'Grady, K. E., Selby, P., Martin, P. R., & Fischer, G. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1005359 · Cited by 986
Increasing deaths from opioid analgesics in the United States
Paulozzi, L. J., Budnitz, D. S., & Xi, Y. (2006) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1276 · Cited by 696
Amato, L., Davoli, M., A.Perucci, C., Ferri, M., Faggiano, F., & P. Mattick, R. (2005) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2005.02.007 · Cited by 567
Acute Pain Management for Patients Receiving Maintenance Methadone or Buprenorphine Therapy
Alford, D. P., Compton, P., & Samet, J. H. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-2-200601170-00010 · Cited by 468
Self-citationMethadone maintenance treatment (MMT): a review of historical and clinical issues.
Joseph, H., Stancliff, S., & Langrod, J. (2000) · PubMed · Cited by 415
Addiction recovery: Its definition and conceptual boundaries
White, W. L. (2007) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.04.015 · Cited by 404
Becker, W. C., Sullivan, L. E., Tetrault, J. M., Desai, R. A., & Fiellin, D. A. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2007.09.018 · Cited by 399
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004147.pub4 · Cited by 370
Woody, G. E., Poole, S. A., Subramaniam, G., Dugosh, K., Bogenschutz, M., Abbott, P., Patkar, A., Publicker, M., McCain, K., Potter, J. S., et al. (2008) · JAMA · doi:10.1001/jama.2008.574 · Cited by 361
Substance use disorder among older adults in the United States in 2020
Han, B., Gfroerer, J. C., Colliver, J. D., & Penne, M. A. (2009) · Addiction · doi:10.1111/j.1360-0443.2008.02411.x · Cited by 337
Jones, H. E., Johnson, R. E., Jasinski, D. R., O’Grady, K. E., Chisholm, C. A., Choo, R. E., Crocetti, M., Dudas, R., Harrow, C., Huestis, M. A., et al. (2005) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2004.11.013 · Cited by 295
QT-Interval Effects of Methadone, Levomethadyl, and Buprenorphine in a Randomized Trial
Wedam, E. F. (2007) · Archives of Internal Medicine · doi:10.1001/archinte.167.22.2469 · Cited by 259
Treatment of Hepatitis C Infection in Injection Drug Users
Backmund, M., Meyer, K., Von Zielonka, M., & Eichenlaub, D. (2001) · Hepatology · doi:10.1053/jhep.2001.25882 · Cited by 256
Use of buprenorphine in pregnancy: patient management and effects on the neonate
JOHNSON, R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00062-0 · Cited by 245
Buprenorphine: how to use it right
JOHNSON, R. (2003) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(03)00060-7 · Cited by 241
Lejeune, C., Simmat-Durand, L., Gourarier, L., & Aubisson, S. (2006) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2005.10.001 · Cited by 239
Opioid dependence treatment: options in pharmacotherapy
Stotts, A. L., Dodrill, C. L., & Kosten, T. R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903037168 · Cited by 222
Amato, L., Minozzi, S., Davoli, M., & Vecchi, S. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005031.pub4 · Cited by 221
Moatti, J. P., Carrieri, M. P., Spire, B., Gastaut, J. A., Cassuto, J. P., & Moreau, J. (2000) · AIDS · doi:10.1097/00002030-200001280-00010 · Cited by 220
Pharmacologic treatments for opioid dependence: detoxification and maintenance options
Kleber, H. D. (2007) · Phlebolymphology · doi:10.31887/dcns.2007.9.4/hkleber · Cited by 211
Marsch, L. A., Bickel, W. K., Badger, G. J., Stothart, M. E., Quesnel, K. J., Stanger, C., & Brooklyn, J. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.10.1157 · Cited by 205
Treatment of opioid-dependent pregnant women: Clinical and research issues
Jones, H. E., Martin, P. R., Heil, S. H., Kaltenbach, K., Selby, P., Coyle, M. G., Stine, S. M., O'Grady, K. E., Arria, A. M., & Fischer, G. (2008) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2007.10.007 · Cited by 191
Kakko, J., Heilig, M., & Sarman, I. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.01.025 · Cited by 186
Pharmacologic treatments for opioid dependence: detoxification and maintenance options
Kleber, H. D. (2007) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2007.9.2/hkleber · Cited by 181
Gender and non‐medical use of prescription opioids: results from a national US survey*
Tetrault, J. M., Desai, R. A., Becker, W. C., Fiellin, D. A., Concato, J., & Sullivan, L. E. (2008) · Addiction · doi:10.1111/j.1360-0443.2007.02056.x · Cited by 169
Long‐Term Treatment with Buprenorphine/Naloxone in Primary Care: Results at 2–5 Years
Fiellin, D. A., Moore, B. A., Sullivan, L. E., Becker, W. C., Pantalon, M. V., Chawarski, M. C., Barry, D. T., O'Connor, P. G., & Schottenfeld, R. S. (2008) · The American Journal on Addictions · doi:10.1080/10550490701860971 · Cited by 162
Sanchez, E. S., Bigbee, J. W., Fobbs, W. C., Robinson, S. E., & Sato‐Bigbee, C. (2008) · Glia · doi:10.1002/glia.20675 · Cited by 145
Buprenorphine maintenance treatment in a primary care setting: outcomes at 1 year.
Soeffing, J. M., Martin, L. D., Fingerhood, M. I., Jasinski, D., & Rastegar, D. (2009) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2009.05.003 · Cited by 132
Neonatal Abstinence Syndrome After Methadone or Buprenorphine Exposure
Jones, H. E., Kaltenbach, K. A., Heil, S. H., Stine, S. M., Coyle, M. G., Arria, A. M., O’Grady, K. E., Selby, P. L., Martin, P., & Fischer, G. (2011) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e318225c419 · Cited by 112
Daley, D. C., Salloum, I. M., Zuckoff, A., Kirisci, L., & Thase, M. E. (1998) · American Journal of Psychiatry · doi:10.1176/ajp.155.11.1611 · Cited by 109
Changing patterns in opioid addiction: characterizing users of oxycodone and other opioids.
Sproule, B. A., Brands, B., Li, S., & Catz-Biro, L. (2009) · PubMed Central · Cited by 106
Neonatal outcome following buprenorphine maintenance during conception and throughout pregnancy
Schindler, S. D., Eder, H., Ortner, R., Rohrmeister, K., Langer, M., & Fischer, G. (2002) · Addiction · doi:10.1046/j.1360-0443.2003.00245.x · Cited by 102
When "enough" is not enough: new perspectives on optimal methadone maintenance dose.
Leavitt, S., Shinderman, M. S., Maxwell, S., Eap, C. B., & Paris, P. (2000) · PubMed · Cited by 100
Lavie, E., Fatseas, M., Denis, C., & Auriacombe, M. (2008) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2008.07.017 · Cited by 100
Comer, S. D., Walker, E. A., & Collins, E. D. (2005) · Psychopharmacology · doi:10.1007/s00213-005-0023-6 · Cited by 98
Kraft, W. K., Dysart, K., Greenspan, J. S., Gibson, E., Kaltenbach, K. A., & Ehrlich, M. E. (2010) · Addiction · doi:10.1111/j.1360-0443.2010.03170.x · Cited by 94
Hepatitis after intravenous buprenorphine misuse in heroin addicts
Berson, A., Gervais, A., Cazals-Hatem, D. L., Boyer, N., Durand, F., Bernuau, J., Marcellin, P., Degott, C., Valla, D. C., & Pessayre, D. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(00)00049-0 · Cited by 93
Sporer, K. A. (2004) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2003.11.006 · Cited by 92
Helm, S., Trescot, A. M., Colson, J., Sehgal, N., & Silverman, S. (2008) · Pain Physician · doi:10.36076/ppj.2008/11/225 · Cited by 87
McCance‐Katz, E. F., Moody, D. E., Morse, G. D., FRIEDLAND, G. H., Pade, P., Baker, J., Alvanzo, A. A. H., Smith, P. F., Ogundele, A., Jatlow, P. I., et al. (2006) · Clinical Infectious Diseases · doi:10.1086/508187 · Cited by 84
McCance‐Katz, E. F. (2005) · Clinical Infectious Diseases · doi:10.1086/429503 · Cited by 77
McCance‐Katz, E. F., Moody, D. E., Smith, P. F., Morse, G. D., Friedland, G., Pade, P., Baker, J., Alvanzo, A. A. H., Jatlow, P. I., & Rainey, P. M. (2006) · Clinical Infectious Diseases · doi:10.1086/508188 · Cited by 76
Update on the pharmacologic management of neonatal abstinence syndrome
Bio, L. L., Siu, A., & Poon, C. Y. (2011) · Journal of Perinatology · doi:10.1038/jp.2011.116 · Cited by 70
Fleming, M. F., Davis, J. M., & Passik, S. D. (2008) · Pain Medicine · doi:10.1111/j.1526-4637.2008.00491.x · Cited by 69
Epidemiological Trends in Abuse and Misuse of Prescription Opioids
Spiller, H. A., Lorenz, D. J., Bailey, E. J., & Dart, R. C. (2009) · Journal of Addictive Diseases · doi:10.1080/10550880902772431 · Cited by 67
Fiellin, D. A. (2007) · Journal of Addiction Medicine · doi:10.1097/adm.0b013e3180473c11 · Cited by 66
Analgesic effects of sublingual buprenorphine
Edge, W. G., COOPER, G. M., & Morgan, M. K. (1979) · Anaesthesia · doi:10.1111/j.1365-2044.1979.tb06325.x · Cited by 66
Helm, S., Trescot, A. M., Colson, J. D., Sehgal, N., & Silverman, S. M. (2008) · PubMed · Cited by 64
Dausey, D. J., & Desai, R. A. (2003) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-200301000-00003 · Cited by 63
Opioid Dependence: Rationale for and Efficacy of Existing and New Treatments
Fiellin, D. A., Friedland, G. H., & Gourevitch, M. N. (2006) · Clinical Infectious Diseases · doi:10.1086/508180 · Cited by 56
Effects of High-Dose Intravenous Buprenorphine in Experienced Opioid Abusers
Umbricht, A., Huestis, M. A., Cone, E. J., & Preston, K. L. (2004) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000138766.15858.c6 · Cited by 54
Medical Consequences of Drug Abuse and Co-Occurring Infections
Khalsa, J. H., Treisman, G. J., McCance‐Katz, E. F., & Tedaldi, E. (2008) · Substance Abuse · doi:10.1080/08897070802218661 · Cited by 54
Gunderson, E. W., & Fiellin, D. A. (2008) · CNS Drugs · doi:10.2165/00023210-200822020-00002 · Cited by 52
Anderson, I. B. (2000) · Western Journal of Medicine · doi:10.1136/ewjm.172.1.43 · Cited by 50
Carrieri, P., Vlahov, D., Dellamonica, P., Gallais, H., Lepeu, G., Spire, B., & Obadia, Y. (2000) · Drug and Alcohol Dependence · doi:10.1016/s0376-8716(00)80007-1 · Cited by 45
Comer, S. D., Sullivan, M. A., & Walker, E. A. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.090423 · Cited by 44
Treatment of Adolescent Opioid Dependence: No Quick Fix
Fiellin, D. A. (2008) · JAMA · doi:10.1001/jama.2008.567 · Cited by 40
Unger, A., Jagsch, R., Jones, H. E., Arria, A. M., Leitich, H., Rohrmeister, K., Aschauer, C., Winklbaur, B., Bäwert, A., & Fischer, G. (2011) · Addiction · doi:10.1111/j.1360-0443.2011.03440.x · Cited by 37
Looking forward and back to relapse: implications for research and practice
Connors, G. J., Longabaugh, R., & Miller, W. R. (1996) · Addiction · doi:10.1046/j.1360-0443.91.12s1.9.x · Cited by 35
Reed, L. J., Glasper, A., de Wet, C., Bearn, J., & Gossop, M. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318032ec2a · Cited by 26
Sublingual buprenorphine as postoperative analgesic: a double‐blind comparison with pethidine
Moa, G., & Zetterström, H. (1990) · Acta Anaesthesiologica Scandinavica · doi:10.1111/j.1399-6576.1990.tb03044.x · Cited by 21
Levy, S., Vaughan, B. L., Angulo, M., & Knight, J. R. (2007) · Journal of Adolescent Health · doi:10.1016/j.jadohealth.2006.11.142 · Cited by 20
Complications infectieuses et mésusage de la buprénorphine à haut dosage
Cazorla, C., de Cardenal, D. G., Schuhmacher, H., Thomas, L., Wack, A., May, T., & Rabaud, C. (2005) · La Presse Médicale · doi:10.1016/s0755-4982(05)84025-4 · Cited by 17
Looking forward and back to relapse: implications for research and practice
Connors, G. J., Longabaugh, R., & Miller, W. R. (1996) · Addiction · doi:10.1111/j.1360-0443.1996.tb02338.x · Cited by 17
A critical appraisal of the Australian comparative trial of methadone and buprenorphine maintenance
Caplehorn, J. R. M., & Deeks, J. J. (2006) · Drug and Alcohol Review · doi:10.1080/09595230600681527 · Cited by 11
Improving the management of opioid-dependent pregnancies
Dashe, J. S., Sheffield, J. S., & Wendel, G. D. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.01.081 · Cited by 7
Cited by
National and state treatment need and capacity for opioid agonist medication-assisted treatment
Jones, C. M., Campopiano, M., Baldwin, G., & McCance-Katz, E. (2015) · American Journal of Public Health · doi:10.2105/ajph.2015.302664 · Cited by 668
Management of opioid use disorders: a national clinical practice guideline
Bruneau, J., Ahamad, K., Goyer, M.-È., Poulin, G., Selby, P., Fischer, B., Wild, T. C., & Wood, E. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.170958 · Cited by 412
Prenatal and Postpartum Care of Women with Substance Use Disorders
Gopman, S. (2014) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2014.02.004 · Cited by 88
Weinstein, Z. M., Gryczynski, G., Cheng, D. M., Quinn, E., Hui, D., Kim, H. W., Labelle, C., & Samet, J. H. (2018) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2018.05.010 · Cited by 23
Metadata
- Authors
- Kraus, M. L., Alford, D. P., Kotz, M. M., Levounis, P., Mandell, T. W., Meyer, M., Salsitz, E. A., Wetterau, N., & Wyatt, S. A.
- Venue
- Journal of Addiction Medicine
- Published
- 2011-12
- Volume
- 5
- Issue
- 4
- Pages
- 254-263
- ISSN
- 1932-0620 (ISSN-L)
- OpenAlex
- W2160744884
- Cited by
- 266
- References
- 69
- FWCI
- 6.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.